Editorial: Don’t rush to rehabilitate Hwang
By Editorial,
Nature
| 01. 21. 2014
An article published on Nature’s website last week has created quite a buzz in South Korea. It details efforts by former Seoul National University cloning specialist Woo Suk Hwang to rehabilitate his scientific career after he was found in 2006 to have been involved in fraud. Some in South Korea are taking the article as a sign that Hwang is now producing great science and is once again lauded by the scientific community. Stock prices of companies with connections to Hwang’s work have apparently jumped. It is as if many of the people talking and writing about the article have not read it. They and others can do so now if they wish: it appears as a News Feature on page 468.
As readers will see, the article is not a show of support for Hwang’s research. Nor is it an attack. It is the story of a rare event: a scientist attempting with some success to dig himself out from the depths of ignominy. It is a journalistic exercise, not a scientific endorsement. And it was commissioned to...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...